Angelica archangelica / Garden Angelica / TumCG Cancer Research Results

Ang, Angelica archangelica / Garden Angelica: Click to Expand ⟱
Features:

Angelica archangelica (Garden angelica) is a medicinal plant whose root, leaf, seed, and essential-oil preparations contain coumarins, furanocoumarins, and volatile terpenes. Major reported constituents include imperatorin, isoimperatorin, xanthotoxin, bergapten, α-pinene, and β-phellandrene. Preclinical studies report anticancer, antimicrobial, anti-inflammatory, antioxidant, and gastrointestinal effects. The plant part and extraction method should be recorded because constituent profiles vary substantially. Angelica archangelica should be kept separate from other Angelica species, including Angelica sinensis. Concentrated preparations may contain phototoxic furanocoumarins and can increase photosensitivity. Research reference; Safety reference.


Angelica archangelica / Garden Angelica — a large aromatic biennial herb in the Apiaceae family used as a culinary botanical and traditional herbal preparation. It is a heterogeneous plant-derived modality rather than a single pharmacological agent; roots, fruits or seeds, leaves, and essential oils have substantially different chemical profiles. Standard names include Angelica archangelica L., garden angelica, European angelica, and the historical synonym Archangelica officinalis. Important constituents include the furanocoumarins imperatorin, isoimperatorin, xanthotoxin, bergapten, and angelicin, together with volatile terpenes such as α-pinene and β-phellandrene. Anticancer evidence applies mainly to chemically undefined root or fruit extracts and cannot automatically be attributed to the whole plant, essential oil, or any single constituent.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptotic signaling in susceptible cancer cells, including caspase activation, mitochondrial dysfunction, and increased pro-apoptotic signaling.
  2. Suppression of tumor-cell proliferation and clonogenic survival, with cell-cycle disruption reported in extract-treated breast and leukemia models.
  3. Modulation of oxidative stress and mitochondrial function, potentially contributing to apoptosis; the direction and importance of ROS remain extract-, concentration-, and model-dependent.
  4. Possible inhibition of inflammatory and survival signaling by coumarins and furanocoumarins, including NF-κB-, MAPK-, and Akt-related pathways; direct evidence for standardized A. archangelica preparations is limited.
  5. Antimicrobial activity of volatile-oil constituents through membrane disruption and related nonspecific physicochemical effects.

Bioavailability / PK relevance: Human pharmacokinetic data for standardized A. archangelica extracts are insufficient. Exposure varies markedly with plant part, cultivar, geography, harvest conditions, and extraction method. Lipophilic furanocoumarins and essential-oil terpenes may be absorbed, but metabolism and systemic concentrations after ordinary oral products are poorly characterized. Root powder, hydroalcoholic extract, essential oil, and isolated furanocoumarins should be treated as distinct preparations.

In-vitro vs systemic exposure relevance: Most anticancer findings were generated using concentrated extracts directly applied to cultured cells. These exposures cannot presently be mapped reliably to achievable human plasma or tissue concentrations. Essential-oil antimicrobial concentrations and isolated-compound experiments are especially unlikely to represent exposure from culinary use. The available evidence therefore supports mechanistic plausibility, not a clinically validated anticancer dose.

Clinical evidence status: Preclinical for cancer. Evidence includes cancer-cell experiments and limited animal tumor studies, without convincing human oncology trials. Small randomized and observational human studies have evaluated a combination supplement containing ferulic acid plus A. archangelica extract in mild cognitive impairment or dementia-related symptoms, but these studies do not establish an independent effect of angelica. It is not an approved cancer therapy or established adjunctive oncology treatment.

Safety and deployment status: Culinary use and traditional herbal use do not establish the safety of concentrated extracts or essential oils. Furanocoumarins can produce UVA-dependent phototoxicity and photogenotoxicity; concentrated preparations may increase photosensitivity, and exposure to strong sunlight or UVA is a material safety concern. Botanical misidentification is also important because Apiaceae includes highly toxic look-alike plants. Safety in pregnancy, breastfeeding, children, and long-term high-dose use is inadequately defined.



Angelica archangelica Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Apoptosis Signaling Caspases ↑; apoptotic death ↑ Insufficient species-specific evidence R, G Promotes programmed cancer-cell death Reported with root and fruit extracts in breast-cancer and leukemia models. Extract composition was not consistently standardized.
2 Mitochondrial Apoptosis Mitochondrial integrity ↓; pro-apoptotic signaling ↑ ↔ or uncertain R, G Supports intrinsic apoptosis Likely contributes to extract-induced cytotoxicity, but the responsible constituent and precise mitochondrial targets remain incompletely resolved.
3 Proliferation and Clonogenic Survival Proliferation ↓; colony formation ↓ Insufficient comparative evidence G Restricts tumor-cell expansion Observed preclinically. Selectivity relative to normal proliferating tissue is not sufficiently established.
4 Cell-Cycle Regulation Cell-cycle progression ↓ (model-dependent) Uncertain R, G Contributes to growth inhibition Cell-cycle effects are reported for extracts or related coumarins, but a reproducible species-wide signature has not been established.
5 Oxidative Stress and ROS ROS ↔ or ↑ (context-dependent) Oxidative injury ↓ in some non-cancer models P, R Context-dependent redox modulation Antioxidant assay activity does not prove systemic antioxidant action. Pro-oxidant involvement in cancer-cell apoptosis remains preparation- and concentration-dependent.
6 NF-κB and Inflammatory Signaling NF-κB ↓; inflammatory mediators ↓ (context-dependent) Inflammation ↓ in selected models R, G May reduce inflammatory and survival signaling More strongly supported for isolated coumarins or other Angelica species than for standardized A. archangelica whole extracts.
7 Akt and MAPK Survival Signaling Akt or MAPK signaling ↓ (model-dependent) Mixed or uncertain R Potentially lowers proliferative and stress-survival signaling Mechanistically plausible from constituent studies, but should not be treated as a firmly established whole-plant mechanism.
8 Microbial Membrane Function Not primarily cancer-specific Host-cell relevance uncertain P Essential-oil antimicrobial activity Volatile terpenes can disrupt microbial membranes at sufficient concentrations. This does not establish systemic anti-infective efficacy.
9 UVA Phototoxicity and DNA Damage Phototoxicity ↑ with UVA Phototoxicity ↑; photogenotoxicity ↑ P, R Furanocoumarin photoactivation Safety liability rather than a validated therapeutic mechanism. Risk depends on furanocoumarin content, exposure, skin or systemic distribution, and UVA dose.
10 Clinical Translation Constraint Effective human exposure unknown Long-term safety incompletely characterized G Limits interpretation and deployment Major constraints include extract heterogeneity, uncertain PK, predominantly preclinical evidence, lack of oncology trials, botanical misidentification, and phototoxic furanocoumarins.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Alzheimer’s disease relevance: Human evidence involves Feru-guard formulations combining ferulic acid with Angelica archangelica extract; consequently, clinical effects cannot be assigned specifically to angelica. A multicenter randomized placebo-controlled study in mild cognitive impairment reported selected cognitive benefits, while an amyloid-imaging study did not demonstrate a clear reduction in cerebral amyloid deposition. Earlier small studies reported possible behavioral or neuropsychiatric improvement in heterogeneous dementia populations. Overall status is small human combination-product evidence with mixed outcomes, not established prevention or treatment of Alzheimer’s disease.

Primary AD-related mechanisms: Proposed mechanisms include AChE inhibition, antioxidant and anti-inflammatory activity, neuronal protection, and possible modulation of amyloid-associated injury. Most are derived from preclinical extract or constituent studies. There is insufficient evidence that orally administered A. archangelica independently reaches the brain at concentrations required for these effects.


Angelica archangelica in Cognitive Disorders

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Cognitive Function Cognition ↑ or ↔ G Possible symptomatic benefit Mixed findings from small studies of a ferulic-acid plus angelica combination. Independent angelica contribution is unresolved.
2 Cholinergic Signaling AChE ↓ (preclinical) R May increase synaptic acetylcholine Primarily extract-level preclinical evidence; human target engagement has not been demonstrated.
3 Neuroinflammation NF-κB ↓; inflammatory mediators ↓ (context-dependent) R, G Potential neuroprotective signaling Evidence is indirect and partly extrapolated from constituent or non-neural models.
4 Oxidative Stress ROS-associated injury ↓ (preclinical) P, R May reduce oxidative neuronal stress Systemic and brain exposure sufficient for this effect has not been established.
5 Amyloid Beta Aβ deposition ↔ or uncertain G No established disease-modifying effect A small human imaging study of the combination product did not provide convincing evidence of reduced amyloid deposition.
6 Clinical Translation Constraint Independent efficacy uncertain G Limits attribution and clinical interpretation Combination with ferulic acid, small samples, heterogeneous diagnoses, limited replication, and uncertain brain PK prevent product-specific conclusions.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
TumCG, Tumor cell growth: Click to Expand ⟱
Source:
Type:
Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M).
Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division).
Scientific Papers found: Click to Expand⟱
6887- Ang,    Medicinal properties of Angelica archangelica root extract: Cytotoxicity in breast cancer cells and its protective effects against in vivo tumor development
- in-vivo, BC, 4T1 - in-vitro, BC, MCF7
BAX↑, Bcl-2↓, cl‑Casp3↑, Dose↝, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

BAX↑, 1,   Bcl-2↓, 1,   cl‑Casp3↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TumCG, Tumor cell growth
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:421  Target#:323  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page